Stockreport

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 [Yahoo! Finance]

Candel Therapeutics, Inc.  (CADL) 
PDF cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent, independent of the specific modal [Read more]